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Abstract
Background
Nintedanib is a multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF); how-
ever, its efficacy and safety for patients with IPF and restricted pulmonary function remain
unclear. Therefore, the objective of this study was to determine the efficacy and safety of
nintedanib for patients with IPF and forced vital capacity (FVC)� 50%.
Methods
This was a multi-center retrospective study performed by the Okayama Respiratory Disease
Study Group. Patients were allocated into FVC� 50% and FVC > 50% groups based on
their predicted FVC. The primary endpoints were FVC changes from baseline after 6 and 12
months.
Results
45 patients were eligible for the study. 18 patients had FVC� 50%, and 27 patients had
FVC > 50%. Overall, 31 and 19 patients underwent pulmonary function tests at 6 and 12
months after initiating nintedanib, respectively. FVC changes from baseline at 6 and 12
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months after initiating nintedanib were comparable between the two groups. Adverse events
were seen in all patients, and the rates of patients who discontinued nintedanib were also
comparable (38.9% vs. 37.0%, p = 1.000). Multiple regression analysis showed that age
and forced expiratory volume in 1 second (FEV1)/FVC were negatively correlated with
changes in FVC at 6 months after initiating nintedanib.
Conclusions
Our data suggest that nintedanib can be a useful agent for IPF patients, including those with
a low FVC, and that age and FEV1/FVC are predictive markers for changes in FVC following
nintedanib treatment.
Introduction
Idiopathic pulmonary fibrosis (IPF) is characterized by chronic and progressive fibrosis of the
lung of unknown etiology [1]. The prognosis of patients with IPF is generally poor, with a
median survival time of 2–3 years [2]. Nintedanib is a multi-kinase inhibitor targeting recep-
tors of vascular epithelial growth factors, platelet-derived growth factors, and fibroblast growth
factors. In Japan, it was approved in 2015 for IPF, based on the results of the INPULSIS-1 and
-2 trials. The INPULSIS trials were multicenter double-blind randomized studies. The primary
endpoint of these studies was the annual decline in forced vital capacity (FVC), which was bet-
ter in the nintedanib group than that in the placebo group [3]. Nintedanib has now been rec-
ommended for treatment according to the IPF guidelines [4–5].
Patients in the INPULSIS trials who had predicted FVC� 50% were excluded, such that it
is unclear whether nintedanib is safe and effective in patients with limited lung function. In
the INPULSIS-ON trial, which is an open-label extension of the INPULSIS trials, patients with
baseline FVC� 50% were the participants; the safety and efficacy of nintedanib for those
patients was demonstrated in an interim analysis [6]. However, only patients whose FVC val-
ues were originally > 50% of the predicted values were eligible for the INPULSIS trials; thus,
the real-world benefit of nintedanib remains unclear for patients with predicted FVC� 50%.
Although some studies exploring this have been reported [7–9], the evidence is insufficient.
Therefore, the aim of this study was to investigate the safety and the efficacy of nintedanib
for patients with IPF and a predicted FVC� 50%.
Our study suggests that nintedanib can be safely administered to patients with IPF and
FVC� 50%. In addition, the change in FVC was comparable between the FVC� 50% and
FVC> 50% groups.
Patients and methods
Patients
All enrolled subjects were IPF patients taking nintedanib and treated at Okayama University
Hospital, Okayama City Hospital, Japan Organization of Occupational Health and Safety Oka-
yama Rosai Hospital, Japanese Red Cross Kobe Hospital, KKR Takamatsu Hospital, National
Hospital Organization Okayama Medical Center, National Hospital Organization Minami-
Okayama Medical Center, or the National Hospital Organization Iwakuni Clinical Center. IPF
was clinically diagnosed based on the 2011 ATS/JRS/ERS/ALAT guidelines [10]. Patients who
met the eligibility criteria of the INPULSIS trials, based on radiological findings, were
included, i.e., presence of a reticular abnormality and traction bronchiectasis consistent with
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fibrosis showing basal and peripheral predominance; absence of atypical features, specifically
nodules and consolidation, and ground glass opacity (where present) that was less extensive
than reticular opacity [3]. All patients underwent high-resolution computed tomography at
the time of diagnosis, and as well as at least one pulmonary function test between 3 months
before and 1 week after initiating nintedanib. The patients began to use nintedanib between
August 2015 and September 2017.
Study design
Clinical data were collected retrospectively from the patients’ medical records. The primary
endpoint was a decline in FVC at 6 and 12 months after initiating nintedanib. This study
adhered to the principles of the Declaration of Helsinki and was approved by the Institutional
Review Board (IRB) of Okayama University Hospital (no. 1710–038; approved on October 13,
2017), and all of the participating hospitals. All clinical data collected from medical records
were anonymized, and their confidentiality was ensured. The IRB waived the requirement for
written informed consent because this retrospective study provided information disclosure to
the patients with a chance to refuse to participate in the study (opt-out method).
Statistical analysis
Continuous variables are presented as median and range, and categorical variables as numbers
with percentages. Overall survival (OS) was estimated by the Kaplan–Meier method. The sig-
nificance of between group differences was assessed by the Mann–Whitney test for continuous
variables and Fisher’s exact test for categorical variables. The paired t-test was used to compare
paired samples. Before performing the multiple regression analysis, the Kolmogorov–Smirnov
test was used to check whether the distribution of the FVC change data was normal. Pearson’s
correlation coefficients were calculated for each explanatory variable. A multiple regression
analysis was performed with explanatory variables of age and sex, and the two variables with
the two lowest p-values (except age). A p-value < 0.05 was considered significant. All statistical
analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Sai-
tama, Japan) [11], which is a graphical user interface for R version 3.4.1 (R Foundation for Sta-
tistical Computing, Vienna, Austria).
Results
Patient characteristics
The patient characteristics are summarized in Table 1. 45 patients were enrolled in this study
(89% male) with age ranging from 41 to 86 years (median, 69 years). Of the patients, 1 was a
current smoker, 37 were former smokers, and 7 patients had never smoked.
Of the 45 patients, 18 had a predicted FVC� 50%, and 27 had an FVC > 50% (Fig 1). The
number of pack-years was significantly higher, and the forced expiratory volume in 1 second
(FEV1)/FVC was significantly lower, in the FVC> 50% group. Computed tomography
revealed that most of the patients in the FVC > 50% group had a typical interstitial pneumonia
(UIP) pattern (81.9%), compared to only 50% of those in the FVC� 50% group. Emphysema
tended to be more frequently observed in the FVC� 50% group (3 [16.7%]) than the
FVC> 50% (1 [3.7%]) group, but the difference was not statistically significant.
The baseline DLCO was significantly lower in the FVC� 50% group than in the FVC> 50%
group. Patients with pulmonary hypertension exhibit low DLCO values; we thus explored the
pulmonary hypertension statuses of both groups. As shown in Table 1, in patients who under-
went echocardiography, the tricuspid regurgitation pressure gradient (TRPG) (used to
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estimate pulmonary artery pressure) was comparable between the two groups. We also
assessed the pulmonary arterial:aortic diameter ratio; a value > 0.9 is suggestive of pulmonary
hypertension. The proportions of patients with pulmonary arterial: aortic diameter ratio > 0.9
were similar in the two groups. Thus, the difference in the DLCO values between the two groups
was not attributable to pulmonary hypertension in the FVC� 50% group.
Table 1. Patient characteristics.
Total FVC� 50% predicted FVC > 50% predicted P-value
n = 45 n = 18 n = 27
Age, years, median (range) 69 (41–86) 68 (41–80) 70 (53–86) 0.296
Sex, male/female, n (%) 40 (88.9%)/5 (11.1%) 15 (83.3%)/3 (16.7%) 25 (92.6%)/2 (7.4%) 0.375
Smoking history
Current smoker, n (%) 1 (2.2%) 0 (0.0%) 1 (3.7%) 0.651
Former smoker, n (%) 37 (82.2%) 14 (77.8%) 23 (85.2%)
Never smoker, n (%) 7 (15.6%) 4 (22.2%) 3 (11.1%)
Pack-years, median (range) 30.0 (0–126) 12.5 (0–70.5) 38.0 (0–126) 0.018
Body mass index, median (range) 22.6 (13.0–30.5) 21.9 (13.0–30.5) 23.1 (18.1–24.2) 0.412
Body surface area, m2, median (range) 1.65 (1.15–1.96) 1.65 (1.15–1.95) 1.65 (1.29–1.96) 0.804
FVC, ml, median (range) 1950 (510–3660) 1270 (510–1950) 2580 (1180–3660) <0.001
FVC, % predicted, median (range) 60.5 (23.5–92.4) 40.5 (23.5–49.4) 69.4 (51.3–92.4) -
FEV1/FVC, %, median (range) 87.6 (69.8–125.5) 93.3 (81.5–100) 85.3 (69.8–96.6) <0.001
performed DLCO, n (%) 25 (55.6%) 8 (44.4%) 17 (63.0%) 0.241
DLCO, %, median
� 38.3 (5.2–77.1) 31.2 (5.2–57.1) 47.6 (16.5–77.1) 0.031
GAP score, median� 2–6 (5) 4–6 (5) 2–6 (4) 0.053
Performed 6-min walk test, n (%) 24 (53.3%) 11 (61.1%) 13 (48.1%) 0.757
6-min walk distance, m, median (range)�� 317.5 (30–550) 300 (30–400) 360 (60–550) 0.234
Disease severity staging for IPF in Japan [12,13], median (range) �� 4 (1–4) 4 (1–4) 4 (1–4) 0.642
Time since IPF diagnosis 407 (8–2691) 392 (8–2673) 438 (21–2691) 0.847
days, median (range)
Long-term oxygen therapy, n (%) 24 (53.3%) 12 (66.7%) 12 (44.4%) 0.223
Radiological pattern, n (%)
UIP pattern 31 (68.9%) 9 (50.0%) 22 (81.5%) 0.038
possible UIP pattern 6 (13.3%) 5 (27.8%) 1 (3.7%)
inconsistent with UIP pattern 8 (17.8%) 4 (22.2%) 4 (14.8%)
Presence of emphysema, n (%) 4 (8.9%) 3 (16.7%) 1 (3.7%) 0.286
PA/Ao > 0.9, n (%) 21 (46.7%) 9 (50.0%) 12 (44.4%) 0.763
Performed echocardiography, n (%) 14 (31.1%) 5 (29.4%) 9 (33.3%) 0.753
TRPG, mmHg, median (range) 35 (16–61) 30 (20–49) 41 (16–61) 0.461
performed SLB, n (%) 11 (24.4%) 5 (29.4%) 6 (23.1%) 0.732
UIP pattern, n (% of performed SLB) 11 (100%) 5 (100%) 6 (100%) 1.000
Previous pirfenidone use, n (%) 16 (35.6%) 6 (33.3%) 10 (37.0%) 1.000
KL-6, median (range) 1204 (238–3520) 1160.5 (334–3520) 1204 (238–2716) 0.772
Continuous variables are presented as median and range, and categorical variables are presented as numbers with percentages. The significance of the between-group
differences was assessed using the Mann–Whitney test for continuous variables and Fisher’s exact test for categorical variables. Abbreviations: FVC, forced vital
capacity; FEV1, forced expiratory volume in 1 second; DLCO, diffusing capacity for carbon monoxide; IPF, idiopathic pulmonary fibrosis; UIP, usual interstitial
pneumonia; PA/Ao, ratio of pulmonary arterial and aortic diameters; TRPG, tricuspid regurgitation pressure gradient; TRPG, tricuspid regurgitation pressure gradient;
SLB, surgical lung biopsy.
�Data from patients who underwent DLCO testing.
��Data from patients who underwent the 6-min walk test
https://doi.org/10.1371/journal.pone.0236935.t001
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No significant group differences were observed in age, sex, smoking history, body mass
index (BMI), body surface area, time since diagnosis of IPF, or the rate of patients who
received home oxygen therapy.
Clinical course
The clinical course data are shown in Table 2. The median observation period was 441 days in
the overall population. The median OS time since initiating nintedanib was 736 days. Adverse
events were observed in all patients. The first- and second-most frequent adverse events were
an increase of liver enzymes and diarrhea, respectively. Of the patients, 31 and 19 had available
data for pulmonary function tests performed 6 months and 12 months after the initiation of
nintedanib, respectively. The median observation period in the FVC� 50% group was 281.5
days.
FVC changes from baseline to 6 months after initiating nintedanib did not differ signifi-
cantly between the FVC > 50% and� 50% groups (Fig 2A and 2B), and data were available in
74% and 61% of the patients, respectively. The FVC change after 12 months showed a similar
tendency (Fig 2C and 2D); however, fewer data were available in the FVC� 50% group than
in the FVC> 50% group (28% and 52%, respectively). OS was significantly better in the
FVC> 50% group compared to the FVC� 50% group (p = 0.042; Fig 3). The incidence of
adverse events was comparable between the groups, where almost half of the patients were
required to reduce the dose or discontinue the agent (Table 2).
Patients who underwent echocardiography were divided into TRPG� 37 and TRPG < 37
mmHg groups; survival was compared between groups. Patients with higher TRPG values
exhibited somewhat poorer survival than did patients with lower TRPG values, but this differ-
ence was not statistically significant (S1 Fig).
We explored whether nintedanib reduced the declines in FVC (Fig 4). We assessed the rela-
tive changes in predicted FVC values at 6 months before initiation of nintedanib, as well as
Fig 1. Study flow chart.
https://doi.org/10.1371/journal.pone.0236935.g001
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Table 2. Outcomes and adverse events.
Total FVC� 50% predicted FVC > 50% predicted P-value
n = 45 n = 18 n = 27
Outcomes
Medication period in days, median (range) 387 (18–1056) 195.5 (18–742) 414 (36–1,056) 0.179
Observation period in days, median (range) 441 (19–1056) 281.5 (19–742) 449 (74–1,056) 0.056
Overall survival since initiation of nintedanib in days, median (95% CI) 736 (515–779) 650 (135–NA) 742 (492–NA) 0.042
Adverse events
Any, n (%) 45 (100%) 18 (100%) 27 (100%) 1.000
Diarrhea, n (%) 22 (48.8%) 6 (33.3%) 16 (59.3%) 0.130
Nausea, n (%) 7 (15.5%) 3 (16.7%) 4 (14.8%) 1.000
Nasopharyngitis, n (%) 4 (8.9%) 1 (5.6%) 3 (11.1%) 0.640
Bronchitis, n (%) 8 (17.8%) 4 (22.2%) 4 (14.8%) 0.694
Weight loss, n (%) 4 (8.9%) 2 (11.1%) 2 (7.4%) 1.000
Fatigue, n (%) 13 (28.9%) 5 (27.8%) 8 (29.6%) 1.000
Decreased appetite, n (%) 13 (28.9%) 7 (38.9%) 6 (22.2%) 0.317
Liver enzyme elevation, n (%) 28 (62.2%) 11 (61.1%) 17 (63.0%) 1.000
Dose-down or discontinuation due to adverse events, n (%) 23 (51.1%) 9 (50.0%) 14 (51.9%) 1.000
Discontinuation due to adverse events, n (%) 17 (37.8%) 7 (38.9%) 10 (37.0%) 1.000
Continuous variables are presented as median and range, and categorical variables are presented as numbers with percentages. The log-rank test was used to determine
significant differences between groups, except for medication and observation periods (Mann–Whitney test), and adverse events (Fisher’s exact test).
https://doi.org/10.1371/journal.pone.0236935.t002
Fig 2. Differences in the change in Forced Vital Capacity (FVC) between patients with FVC> 50% vs.�50%. A
and C show the decline in FVC from baseline over 6 and 12 months, respectively. B and D show the rate of FVC
decline from baseline over 6 and 12 months, respectively.
https://doi.org/10.1371/journal.pone.0236935.g002
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Fig 3. Kaplan–Meier curve from initiation of nintedanib. The forced vital capacity (FVC)> 50% group survived
longer than the FVC� 50% group.
https://doi.org/10.1371/journal.pone.0236935.g003
Fig 4. FVC changes after initiation of nintedanib. We compared the changes in predicted FVC values after initiation
of nintedanib; the values tended to increase in both the FVC> 50% and FVC� 50% groups. Values are expressed as
the means ± standard error of the means. Before: before initiation of nintedanib. After: after initiation of nintedanib.
https://doi.org/10.1371/journal.pone.0236935.g004
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immediately prior to drug initiation, in the FVC> 50% and FVC� 50% groups. 10 patients in the
FVC> 50% group and 9 patients in the FVC� 50% group underwent pulmonary function testing
prior to initiation of nintedanib; we compared these data to the FVCs after initiation. Fig 4 shows
that the changes in predicted FVC values after initiation of nintedanib tended to increase compared
to those before initiation of nintedanib in both the FVC> 50% and FVC� 50% groups.
In this study, we determined predictors of a change in FVC. Before the analysis, the normal-
ity of the relative change in predicted FVC data was tested by the Kolmogorov–Smirnov test,
which revealed a normal distribution (Fig 5). Pearson’s correlation coefficients were calculated
for each explanatory variable. The univariate analysis showed that age and IPF disease severity
[12,13] were significantly correlated with the relative change in predicted FVC, but BMI, body
surface area, FEV1/FVC, pack-years, FVC, predicted FVC, predicted diffusing capacity for car-
bon monoxide (DLCO), time since diagnosis of IPF, and KL-6 level were not.
A multiple regression analysis was performed, including age, sex, and the two variables
with the two lowest p-values (except age) as explanatory variables (FEV1/FVC and BMI). Age
and FEV1/FVC were negatively correlated with the relative change in predicted FVC 6 months
after initiating nintedanib (Table 3).
Discussion
In this study, we compared the decline in FVC and incidence rates of adverse events between
Japanese patients with IPF and FVC> 50% versus FVC� 50%. The changes in predicted FVC
and incidence of adverse events did not differ significantly between the two groups at 6 or 12
months after initiating nintedanib.
One of the eligibility criteria for the INPULSIS trials [3] was predicted FVC> 50%, and
patients with limited pulmonary function were excluded. An interim analysis of the INPULSI-
S-ON trial [6] revealed the efficacy and the safety of nintedanib in patients with a FVC� 50%
Fig 5. Kolmogorov–Smirnov test to determine the normality of the data for the relative change in predicted FVC
from baseline. The data were normally distributed.
https://doi.org/10.1371/journal.pone.0236935.g005
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for the first time; however, patients who participated in the INPULSIS-ON trial originally had
a FVC > 50% when registered for the INPULSIS trials. In other words, the data from INPUL-
SIS-ON trial might not have reflected real-world data. The results from our study revealed that
nintedanib has efficacy for patients with a low FVC, and also provided protection against
adverse events.
In our study, the change in FVC did not differ significantly between patients with
FVC� 50% and those with FVC> 50% (−56 mL/6 months vs. −22 mL/6 months, respectively;
p = 0.919). The patient characteristics were similar between the groups, except that the
FVC> 50% group had higher pack-years and lower FEV1/FVC values than those in the
FVC� 50% group. Nintedanib tended to reduce the decline in FVC, even in the FVC� 50%
group. Patients who received nintedanib exhibited smaller FVC reductions, compared to
patients not prescribed the drug; this was consistent with the findings of previous studies
[6,8,9]. The effects of nintedanib in the FVC� 50% group were also comparable to those of
previous studies [6,8,9]. In the interim analysis of the INPULSIS-ON trial, nintedanib was effi-
cacious even in the FVC� 50% group, as seen in the FVC> 50% group [6]. Our data and a
previous report indicate that nintedanib is effective even in patients with a lower FVC.
No group differences in adverse events or the rate of patients requiring a dose reduction or
discontinuation of nintedanib were observed. In the interim analysis of the INPULSIS-ON
trial, patients who experienced adverse events leading to treatment discontinuation were more
frequent in the FVC� 50% group [6]. The same tendency has been reported in other studies
[8,9]. We consider that nintedanib must be used carefully, but can be used safely even in
patients with a low FVC.
Here, we discuss the reason why the FVC> 50% group had higher pack-years and lower
FEV1/FVC values than those in the FVC� 50% group in our study. Although most of the
Table 3. Pearson’s correlation of variables with predicted FVC change at 6 months and results of multiple regres-
sion analysis.
Variables Correlation coefficient P-value
Age, years −0.551 0.001
Sex (male: 1, female: 0) −0.020 0.914
Pack-years 0.156 0.402
Body mass index 0.254 0.167
Body surface area, m2 0.245 0.184
FVC, ml 0.189 0.309
FVC, % predicted 0.054 0.772
FEV1/FVC, % −0.274 0.136
Time since IPF diagnosis, days −0.192 0.302
Long-term oxygen therapy (yes: 1, no: 0) 0.234 0.205
Previous pirfenidone use (yes: 1, no: 0) 0.055 0.770
Multivariate analysis B P-value
Age, years −1.238 <0.001
Sex (male: 1, female: 0) −13.29 0.068
Body mass index 1.234 0.125
FEV1/FVC, % −0.888 <0.001
Pearson’s correlation coefficient was calculated for each explanatory variable, and multiple regression analyses
included age, sex, body mass index, and FEV1/FVC; the two variables with the two lowest p-values (except age) were
used as explanatory variables. Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second;
IPF, idiopathic pulmonary fibrosis.
https://doi.org/10.1371/journal.pone.0236935.t003
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patients had the UIP radiological pattern, they may have had a complex pathophysiology com-
prising chronic obstructive pulmonary disease (COPD) caused by smoking; patients with IPF
and COPD may have a FEV1/FVC ratio in the normal range, an entity known as combined
pulmonary fibrosis and emphysema (CPFE) [14]. Given that only 1 patient in the FVC> 50%
group had emphysema, some of the patients may have had chronic bronchitis, which is one of
the phenotypes of COPD in which emphysema does not develop.
In this study, we determined predictors of a change in FVC in an exploratory analysis. In a
previous report, predictors of a change in FVC were unclear in nintedanib responders and
non-responders [15]. We performed a multiple regression analysis on the relative change in
predicted FVC as the outcome variable; age and FEV1/FVC were negatively correlated with
the change in FVC at 6 months after initiating nintedanib. In other words, the patients with
higher age and higher FEV1/FVC experienced a more severe decline in FVC. Several studies
have demonstrated that a lower FEV1/FVC is associated with a better prognosis in patients
with IPF [16–18]; however, the reason remains unclear. One suggested mechanism is that a
lower FEV1/FVC might reflect a complex pathophysiology including COPD as mentioned
above. A lower FEV1/FVC suggests the existence of CPFE, making an FVC apparently higher;
however, only 1 of our patients was diagnosed with COPD, and only 3 (16.7%) and 1 (3.7%)
patients with FVC� 50% and> 50%, respectively, exhibited emphysematous changes in
radiological assessments (Table 1). In a previous study that reported that lower FEV1/FVC
indicates a better IPF prognosis, only 8.2% of lower FEV1/FVC cases had emphysema [18].
Therefore, that study and the present study suggest that FEV1/FVC is an important prognostic
factor regardless of the presence or absence of emphysema. A clinical trial of predictors of nin-
tedanib efficacy is currently ongoing (NCT 02788474).
Some limitations of this study should be discussed. First, it used a retrospective design and
the sample size was small. Second, some patients did not undergo DLCO testing. Patients with
DLCO� 30% should be regarded as having low pulmonary function, as they were excluded
from INPULSIS trials. However, we did not allocate them to the low pulmonary function
group, as> 40% of all patients had an unknown DLCO. Third, not all of the patients were able
to undergo pulmonary function tests at 6 and 12 months after initiating nintedanib, and the
follow-up period was shorter than 12 months in the FVC� 50% group (281.5 days) because of
their poorer general condition and worse OS, as shown in Fig 3; therefore, the potential bias in
our study should be given due consideration.
Conclusions
Nintedanib is a good choice for treating IPF, even in patients with FVC� 50%, and that the
age and FEV1/FVC are predictive markers of the efficacy of nintedanib. However, the evidence
may at present be insufficient; thus, additional studies are warranted.
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higher TRPG values tended to exhibit poorer survival than patients with lower TRPG values
(also 7 patients), but this difference was not statistically significant.
(TIF)
S1 Appendix.
(XLSX)
S1 Data.
(XLSX)
PLOS ONE Effects of nintedanib in IPF patients with low FVC
PLOS ONE | https://doi.org/10.1371/journal.pone.0236935 August 27, 2020 10 / 12
Acknowledgments
We would like to thank all members of the Okayama Respiratory Disease Study Group
(ORDSG). Members who contributed to our study are listed in S1 Appendix. All authors
belong to the ORDSG, and the lead author is Katsuyuki Kiura (kkiura@md.okayama-u.ac.jp).
Author Contributions
Conceptualization: Satoru Senoo, Nobuaki Miyahara, Akihiko Taniguchi, Naohiro Oda,
Junko Itano, Hisao Higo, Toshimitsu Suwaki, Kazuhiro Kajimoto, Hirohisa Ichikawa,
Takuo Shibayama, Yasushi Tanimoto, Shoichi Kuyama, Arihiko Kanehiro, Yoshinobu
Maeda, Katsuyuki Kiura.
Data curation: Satoru Senoo, Nobuaki Miyahara, Akihiko Taniguchi, Naohiro Oda, Junko
Itano, Hisao Higo, Naofumi Hara, Hiromi Watanabe, Hirohisa Kano, Toshimitsu Suwaki,
Yasuko Fuchimoto, Kazuhiro Kajimoto, Hirohisa Ichikawa, Kenichiro Kudo, Takuo Shi-
bayama, Yasushi Tanimoto, Shoichi Kuyama.
Formal analysis: Satoru Senoo, Nobuaki Miyahara, Akihiko Taniguchi, Hisao Higo, Naofumi
Hara, Hiromi Watanabe, Hirohisa Kano, Yasuko Fuchimoto, Kenichiro Kudo.
Investigation: Satoru Senoo, Nobuaki Miyahara, Akihiko Taniguchi, Naohiro Oda, Junko
Itano, Hisao Higo.
Methodology: Satoru Senoo, Nobuaki Miyahara, Akihiko Taniguchi, Naohiro Oda, Junko
Itano, Hisao Higo.
Project administration: Nobuaki Miyahara, Akihiko Taniguchi, Arihiko Kanehiro, Yoshi-
nobu Maeda, Katsuyuki Kiura.
Supervision: Nobuaki Miyahara, Arihiko Kanehiro, Yoshinobu Maeda, Katsuyuki Kiura.
Validation: Satoru Senoo, Nobuaki Miyahara.
Visualization: Satoru Senoo, Nobuaki Miyahara, Akihiko Taniguchi, Yoshinobu Maeda, Kat-
suyuki Kiura.
Writing – original draft: Satoru Senoo, Nobuaki Miyahara.
Writing – review & editing: Satoru Senoo, Nobuaki Miyahara, Akihiko Taniguchi, Naohiro
Oda, Junko Itano, Hisao Higo, Naofumi Hara, Hiromi Watanabe, Hirohisa Kano, Toshi-
mitsu Suwaki, Yasuko Fuchimoto, Kazuhiro Kajimoto, Hirohisa Ichikawa, Kenichiro
Kudo, Takuo Shibayama, Yasushi Tanimoto, Shoichi Kuyama, Arihiko Kanehiro, Yoshi-
nobu Maeda, Katsuyuki Kiura.
References
1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic
pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care
Med 2018; 198:e44–e68. https://doi.org/10.1164/rccm.201807-1255ST PMID: 30168753
2. Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, et al. Epidemiologic survey of Japa-
nese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Rspir Crit
Care Med 2014; 190:773–779.
3. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of ninteda-
nib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071–2082. https://doi.org/10.1056/
NEJMoa1402584 PMID: 24836310
4. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT
clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical
PLOS ONE Effects of nintedanib in IPF patients with low FVC
PLOS ONE | https://doi.org/10.1371/journal.pone.0236935 August 27, 2020 11 / 12
practice guideline. Am J Respir Crit Care Med 2015; 192:e3–e19. https://doi.org/10.1164/rccm.201506-
1063ST PMID: 26177183
5. Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, et al. Japanese guideline for the treat-
ment of idiopathic pulmonary fibrosis. Respir Investig 2018; 56:268–291. https://doi.org/10.1016/j.
resinv.2018.03.003 PMID: 29980444
6. Wuyts WA, Kolb M, Stowasser S, Stansen W, Huggins JT, Raghu G. First data on efficacy and safety of
nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of� 50% of the pre-
dicted value. Lung 2016; 194:739–743. https://doi.org/10.1007/s00408-016-9912-1 PMID: 27377558
7. Harari S, Caminati A, Poletti V, Confalonieri M, Gasparini S, Lacedonia D, et al. A real-life multicenter
national study on nintedanib in severe idiopathic pulmonary fibrosis. Respiration 2018; 95:433–440.
https://doi.org/10.1159/000487711 PMID: 29587263
8. Yoon HY, Park S, Kim DS, Song JW. Efficacy and safety of nintedanib in advanced idiopathic pulmo-
nary fibrosis. Respir Res 2018; 19:203. https://doi.org/10.1186/s12931-018-0907-8 PMID: 30340638
9. Abe M, Tsushima K, Sakayori M, Suzuki K, Ikari J, Terada J, et al. Utility of nintedanib for severe idio-
pathic pulmonary fibrosis: A single-center retrospective study. Drug Des Devel Ther 2018; 12:3369–
3375. https://doi.org/10.2147/DDDT.S179427 PMID: 30349191
10. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT
statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management.
Am J Respir Crit Care Med 2011; 183:788–824. https://doi.org/10.1164/rccm.2009-040GL PMID:
21471066
11. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant 2013; 48:452–458. https://doi.org/10.1038/bmt.2012.244 PMID: 23208313
12. Japanese Respiratory Society’s Committee formulating diagnosis and treatment guideline for diffuse
lung diseases. Clinical diagnostic and treatment guidance for idiopathic interstitial pneumonias. Tokyo,
Nankodo; 2004.
13. Homma S, Sugino K, Sakamoto S. The usefulness of a disease severity staging classification system
for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment.
Respir Investig 2015; 53:7–12. https://doi.org/10.1016/j.resinv.2014.08.003 PMID: 25542598
14. Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema: An experimental and clinically rel-
evant phenotype. Am J Respir Crit Care Med 2005; 172:1605. https://doi.org/10.1164/ajrccm.172.12.
1605a PMID: 16339012
15. Flaherty KR, Kolb M, Vancheri C, Tang W, Conoscenti CS, Richeldi L. Stability or improvement in forced
vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. Eur Respir J 2018; 52:
https://doi.org/10.1183/13993003.02593–2017
16. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, et al. Determinants of
survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149:450–454. https://doi.org/
10.1164/ajrccm.149.2.8306044 PMID: 8306044
17. King TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary
fibrosis: Scoring system and survival model. Am J Respir Crit Care Med 2001; 164:1171–1181. https://
doi.org/10.1164/ajrccm.164.7.2003140 PMID: 11673205
18. Nishiyama O, Yamazaki R, Sano A, Yamagata T, Sano H, Iwanaga T, et al. Prognostic value of forced
expiratory volume in 1 second/forced vital capacity in idiopathic pulmonary fibrosis. Chron Respir Dis
2016; 13:40–47. https://doi.org/10.1177/1479972315603714 PMID: 26374300
PLOS ONE Effects of nintedanib in IPF patients with low FVC
PLOS ONE | https://doi.org/10.1371/journal.pone.0236935 August 27, 2020 12 / 12
